OTCMKTS:NGENF NervGen Pharma (NGENF) Stock Price, News & Analysis $5.84 0.00 (0.00%) As of 09/21/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About NervGen Pharma Stock (OTCMKTS:NGENF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NervGen Pharma alerts:Sign Up Key Stats Today's Range$5.84▼$5.8450-Day Range$5.84▼$5.8452-Week Range$1.50▼$6.10VolumeN/AAverage Volume134,507 shsMarket Capitalization$360.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NervGen Pharma Corp. (OTCMKTS:NGENF) is a clinical-stage biotechnology company focused on developing treatments that promote repair and recovery following damage to the nervous system. The company is headquartered in Vancouver, British Columbia, Canada. NervGen’s lead product candidate is NVG-291, a proprietary therapeutic peptide designed to support neuroregeneration by influencing biological mechanisms involved in nerve repair, including axonal growth, remyelination and the formation of functional neural connections. The company has primarily focused its clinical development efforts on conditions involving nervous system injury, including spinal cord injury. NervGen’s research programs are intended to address significant unmet medical needs in people whose neurological function has been impaired by trauma or disease.AI Generated. May Contain Errors. Read More Receive NGENF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGENF Stock News HeadlinesHC Wainwright & Co. initiates coverage of NervGen Pharma (NGEN) with buy recommendationApril 28, 2026 | msn.comNervGen beruft Keith Vendola zum neuen FinanzvorstandApril 27, 2026 | de.investing.comRothschilds and BlackRock are buying this high yield gold playMost stocks yield under 2%. Even gold stocks average less than 1%. One gold security, backed by one of the world's best mines, is yielding upwards of 10%. The Rothschilds, Vanguard, and BlackRock have already taken positions. With at least 8 more years of production ahead, early investors could see substantial total returns as prices start to move.September 22 at 1:00 AM | Golden Portfolio (Ad)NervGen Pharma Names Keith Vendola Chief Financial OfficerApril 27, 2026 | marketwatch.comNervGen Pharma Corp.: NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial OfficerApril 27, 2026 | finanznachrichten.deNervGen Pharma to Participate in the H.C. Wainwright ‘HCW@Home’ Series and the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 13, 2026 | financialpost.comFAnalysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN)April 10, 2026 | theglobeandmail.comNervGen: FDA stimmt zulassungsrelevanter Phase-3-Studie für Tetraplegie-Medikament zuApril 7, 2026 | de.investing.comSee More Headlines NGENF Stock Analysis - Frequently Asked Questions How have NGENF shares performed this year? NervGen Pharma's stock was trading at $5.60 on January 1st, 2026. Since then, NGENF shares have increased by 4.3% and is now trading at $5.84. How do I buy shares of NervGen Pharma? Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:NGENF CIK1751912 Webwww.nervgen.com Phone(778) 731-1711FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.07 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-56.59% Debt Debt-to-Equity Ratio0.04 Current Ratio11.21 Quick Ratio11.21 Sales & Book Value Annual Sales$150 thousand Price / Sales2,404.91 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares61,770,000Free FloatN/AMarket Cap$360.74 million OptionableNot Optionable BetaN/A Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:NGENF) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | Sponsored“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown,...Brownstone Research | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredWhy Did Trump's Sons Put Money Into THIS Drone Company?Eric Trump and Donald Trump Jr. are reportedly backing an American drone manufacturer competing for a share of...Tim Sykes | SponsoredCFA: Decentralized AI is the Next WaveDon't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGENF Stock Alerts